Concepedia

Peter Lin

PL

Statistics

Publications

28

Citations

2.2K

H-Index

18

Active since

2000

Affiliations

Liverpool Hospital(Current)

UNSW Sydney

Western Sydney University

Calvary Mater Newcastle Hospital

Ingham Institute

Peter Lin is an author at Liverpool Hospital specializing in medicine, oncology, and diagnostic radiology.

ORCID

Publications per year

2000–2025

28

Publications

28

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

, , +12

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

, , +16

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 155 citations

, , +12

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Arun Azad, Mathias Bressel, Hsiang Tan et al. · The Lancet Oncology · 2024 · 111 citations

, , +12

PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study

Andrew M. Scott, Dishan H. Gunawardana, Dylan Bartholomeusz et al. · Journal of Nuclear Medicine · 2008 · 96 citations · Full text

, , +13

1–5 of 28